16 September 2026 editorial review · Item
Abatacept (CTLA4-Ig): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: reviewed; no confirmed content change. Current item
lastReviewed: 2026-08-27. - Claim check: Historical randomized outcomes checked: ~9.6-month lag in C-peptide decline; stage-1 prevention HR 0.702, P=.11 did not establish prevention. C-peptide preservation is not prevention approval.
- Registry NCT00505375: COMPLETED; updated 2020-05-06; enrollment 112 (ACTUAL); primary completion 2012-05 (ACTUAL); results posted.
- Registry NCT01773707: COMPLETED; updated 2024-06-06; enrollment 212 (ACTUAL); primary completion 2021-12-14 (ACTUAL); results posted.
- Primary publication/regulatory sources checked or consulted: dbi20-0054; dci24-0042; S0140-6736%2811%2960886-6; dc13-0604; dc22-2200.